Cochrane · systematic review · CD013252
Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis
Al Said, S, Alabed, S, Kaier, K, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
28
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 4 · 14.3%Low 18 · 64.3%Moderate 6 · 21.4%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings – death from cardiovascular causes
Population: adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
APX vs VKA | no estimate extracted | 2 studies · 4930 participants | Moderate Downgraded: risk of bias, imprecision |
RVX (high dose, 10 mg to 20 mg) vs VKA | no estimate extracted | 2 studies · 1542 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
RVX (low dose, 2.5 mg) vs VKA | no estimate extracted | 1 study · 1399 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings – myocardial infarction
Population: adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
APX vs VKA | no estimate extracted | 2 studies · 4930 participants | Moderate Downgraded: risk of bias, imprecision |
RVX (high dose, 10 mg to 20 mg) vs VKA | no estimate extracted | 2 studies · 1542 participants | Very low Downgraded: imprecision |
RVX (low dose, 2.5 mg) vs VKA | no estimate extracted | 1 study · 1399 participants | Low Downgraded: risk of bias, imprecision |
DAB (low dose, 110 mg) vs VKA | no estimate extracted | 1 study · 1962 participants | Low Downgraded: risk of bias, imprecision |
DAB (high dose, 150 mg) vs VKA | no estimate extracted | 1 study · 1527 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings – stroke
Population: adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
APX vs VKA | no estimate extracted | 2 studies · 4930 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
RVX (high dose, 10 mg to 20 mg) vs VKA | no estimate extracted | 2 studies · 1546 participants | Very low Downgraded: risk of bias, imprecision |
RVX (low dose, 2.5 mg) vs VKA | no estimate extracted | 1 study · 1399 participants | Low Downgraded: risk of bias, imprecision |
DAB (low dose, 110 mg) vs VKA | no estimate extracted | 1 study · 1962 participants | Low Downgraded: risk of bias, imprecision |
DAB (high dose, 150 mg) vs VKA | no estimate extracted | 1 study · 1527 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings – major bleeding
Population: adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
APX vs VKA | no estimate extracted | 2 studies · 4865 participants | Moderate Downgraded: risk of bias, imprecision |
RVX (high dose, 10 mg to 20 mg) vs VKA | no estimate extracted | 2 studies · 1546 participants | Very low Downgraded: risk of bias, imprecision |
RVX (low dose, 2.5 mg) vs VKA | no estimate extracted | 1 study · 1403 participants | Low Downgraded: risk of bias, imprecision |
DAB (low dose, 110 mg) vs VKA | no estimate extracted | 1 study · 1962 participants | Moderate Downgraded: risk of bias, imprecision |
DAB (high dose, 150 mg) vs VKA | no estimate extracted | 1 study · 1527 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings – death from any cause
Population: adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
APX vs VKA | no estimate extracted | 2 studies · 4930 participants | Moderate Downgraded: risk of bias, imprecision |
RVX (high dose, 10 mg to 20 mg) vs VKA | no estimate extracted | 1 study · 1393 participants | Low Downgraded: risk of bias, imprecision |
RVX (low dose, 2.5 mg) vs VKA | no estimate extracted | 1 study · 1403 participants | Low Downgraded: risk of bias, imprecision |
DAB (low dose, 110 mg) vs VKA | no estimate extracted | 1 study · 1962 participants | Low Downgraded: risk of bias, imprecision |
DAB (high dose, 150 mg) vs VKA | no estimate extracted | 1 study · 1527 participants | Low Downgraded: risk of bias, imprecision |
Summary of findings – stent thrombosis
Population: adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
APX vs VKA | no estimate extracted | 1 study · 4614 participants | Moderate Downgraded: risk of bias |
RVX (high dose, 10 mg to 20 mg) vs VKA | no estimate extracted | 1 study · 1389 participants | Low Downgraded: risk of bias, imprecision |
RVX (low dose, 2.5 mg) vs VKA | no estimate extracted | 1 study · 1399 participants | Low Downgraded: risk of bias, imprecision |
DAB (low dose, 110 mg) vs VKA | no estimate extracted | 1 study · 1962 participants | Low Downgraded: risk of bias, imprecision |
DAB (high dose, 150 mg) vs VKA | no estimate extracted | 1 study · 1527 participants | Low Downgraded: risk of bias, imprecision |